Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen

COR raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 after third-quarter results beat expectations. The pharmaceutical distributor's U.S. segment profit climbed 15.9%, powered by specialty sales and GLP-1 demand, while international operating income jumped 20.8%.

The升级 follows momentum in Cencora's specialty business, which continues to capture share of high-growth GLP-1 diabetes and weight-loss therapies. Despite the strength, the company flagged margin pressure from lower-margin GLP-1 products, manufacturer price cuts, and elevated financing costs—factors that limit how much upside translates to the bottom line.

Zacks Investment Research maintains a Rank #3 (Hold) rating on the stock, signaling neutral near-term expectations despite the raised outlook.

The guidance lift represents a clear operational win, particularly in specialty pharma, but the offsetting headwinds suggest the company is trading margin for volume growth. COR shares have tracked the broader healthcare distribution peer group, which includes MCK and CAH, as all three navigate similar GLP-1 tailwinds and pricing dynamics.